Regenerative Medicine Offers a New Option for Musculoskeletal Pain Care

Issued by: Marketing and Public Relations Department, ECM Biomedical

TAIPEI — With advances in regenerative medicine, human-derived amniotic membrane tissue has increasingly been applied in rehabilitation medicine and the management of musculoskeletal pain, emerging as a promising option for minimally invasive treatment. Multiple international studies published over the past five years have demonstrated the potential clinical benefits of amniotic membrane allografts in reducing pain, supporting tissue repair, and improving physical function.

According to a systematic review and meta-analysis published in the American Journal of Physical Medicine & Rehabilitation, the use of amniotic membrane allografts in patients with degenerative musculoskeletal conditions was associated with significant improvements in pain, physical function, and quality of life. These findings highlight the growing clinical value of amniotic membrane tissue in rehabilitation medicine.

Common Clinical Applications

Amniotic membrane tissue has been applied in the management of common musculoskeletal conditions, including knee osteoarthritis, plantar fasciitis, and soft-tissue injuries. Clinical studies have shown that injections of amniotic membrane allografts may help alleviate pain and improve joint function in patients with knee osteoarthritis. In patients with plantar fasciitis, minimally invasive procedures combined with amniotic membrane injections have also demonstrated favorable short-term pain relief.

An Alternative to Conventional Corticosteroid Treatment

In some patients, amniotic membrane injections have demonstrated pain relief and functional improvement comparable to conventional corticosteroid treatment, with certain studies reporting more sustained benefits during follow-up. These findings suggest that amniotic membrane tissue may offer additional value as a minimally invasive treatment option.

Amniotic membrane tissue contains a range of bioactive components and a naturally derived extracellular matrix (ECM), providing a supportive microenvironment for tissue repair. Its low immunogenicity has also made it a biomaterial of considerable interest in regenerative medicine. When administered through minimally invasive injection or used in conjunction with surgical procedures, amniotic membrane tissue may help modulate inflammatory responses, support the tissue-repair process, and enhance the overall quality of care.

As populations continue to age, joint and muscle-related conditions are becoming increasingly prevalent. The expanding application of amniotic membrane tissue in minimally invasive rehabilitation treatments is broadening its clinical value and offering patients with musculoskeletal pain a more diverse range of promising treatment options.